Biodesix Q2 2026 net loss narrows 37% to $7.3 million; revenue climbs 34% to $26.9 million

• Biodesix posted Q2 2026 revenue of USD 26.9 million, up 34% year over year; GAAP net loss narrowed 37% to USD 7.3 million.
• Gross margin improved 2 percentage points to 82%, as diagnostic testing volumes climbed 38% to 20,900 on expanded payer coverage.
• Diagnostic Testing revenue rose 42% to USD 25.4 million, while Development Services revenue fell to USD 1.5 million from USD 2.1 million on project timing.
• Non-GAAP adjusted EBITDA loss narrowed 56% to USD 3.2 million; cash and cash equivalents increased 17% to USD 30 million, including USD 6.5 million from the at-the-market program.
• Biodesix maintained FY 2026 revenue guidance of USD 108 million to USD 114 million, targeting roughly 80% gross margin and continued adjusted EBITDA improvement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051601PRIMZONEFULLFEED9801945) on August 05, 2026, and is solely responsible for the information contained therein.